Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).

Lebbe C, Lorigan P, Ascierto P, Testori A, Bédane C, Middleton M, van Baardewijk M, Konto C, Dueymes A, Maio M.

Eur J Cancer. 2012 Nov;48(17):3205-14. doi: 10.1016/j.ejca.2012.05.010. Epub 2012 Jun 27.

PMID:
22742880
[PubMed - indexed for MEDLINE]
2.

Treatment patterns and outcomes in patients with advanced melanoma in France.

Bedane C, Leccia MT, Sassolas B, Bregman B, Lebbé C; French investigators of the MELODY study.

Curr Med Res Opin. 2013 Oct;29(10):1297-305. doi: 10.1185/03007995.2013.820693. Epub 2013 Jul 26.

PMID:
23808961
[PubMed - indexed for MEDLINE]
3.

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P.

Am J Clin Oncol. 2011 Dec;34(6):603-10. doi: 10.1097/COC.0b013e3181f9456a.

PMID:
21150567
[PubMed - indexed for MEDLINE]
4.

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).

Johnston K, Levy AR, Lorigan P, Maio M, Lebbe C, Middleton M, Testori A, Bédane C, Konto C, Dueymes A, Sbarigia U, van Baardewijk M.

Eur J Cancer. 2012 Sep;48(14):2175-82. doi: 10.1016/j.ejca.2012.03.003. Epub 2012 Apr 3.

PMID:
22480965
[PubMed - indexed for MEDLINE]
5.

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.

Lorigan P, Marples M, Harries M, Wagstaff J, Dalgleish AG, Osborne R, Maraveyas A, Nicholson S, Davidson N, Wang Q, Pericleous L, Bapat U, Middleton MR.

Br J Dermatol. 2014 Jan;170(1):87-95. doi: 10.1111/bjd.12503.

PMID:
23855404
[PubMed - indexed for MEDLINE]
6.

The cost of unresectable stage III or stage IV melanoma in Italy.

Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C.

J Exp Clin Cancer Res. 2012 Nov 1;31:91. doi: 10.1186/1756-9966-31-91.

PMID:
23116062
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Metastatic melanoma: a regional review and future directions.

Khan KH, Goody RB, Hameed H, Jalil A, Coyle VM, McAleer JJ.

Tumori. 2012 Sep-Oct;98(5):575-80. doi: 10.1700/1190.13197.

PMID:
23235751
[PubMed - indexed for MEDLINE]
8.

Prognostic factors in 1,521 melanoma patients with distant metastases.

Barth A, Wanek LA, Morton DL.

J Am Coll Surg. 1995 Sep;181(3):193-201.

PMID:
7670677
[PubMed - indexed for MEDLINE]
9.

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L.

J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9.

PMID:
9660028
[PubMed - indexed for MEDLINE]
10.

Metastasectomy for recurrent stage IV melanoma.

Ollila DW, Hsueh EC, Stern SL, Morton DL.

J Surg Oncol. 1999 Aug;71(4):209-13.

PMID:
10440757
[PubMed - indexed for MEDLINE]
11.

Low-dose adjuvant interferon for stage III malignant melanoma.

Inman JL, Russell GB, Savage P, Levine EA.

Am Surg. 2003 Feb;69(2):127-30.

PMID:
12641352
[PubMed - indexed for MEDLINE]
12.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
13.

Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.

Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):607-18.

PMID:
10348291
[PubMed - indexed for MEDLINE]
14.

Isolated limb perfusion for unresectable melanoma of the extremities.

Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB.

Arch Surg. 2004 Nov;139(11):1237-42.

PMID:
15545572
[PubMed - indexed for MEDLINE]
15.

[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Chinese.

PMID:
21875471
[PubMed - indexed for MEDLINE]
16.

TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.

Hsueh EC, Gupta RK, Qi K, Yee R, Leopoldo ZC, Morton DL.

Cancer J Sci Am. 1997 Nov-Dec;3(6):364-70.

PMID:
9403050
[PubMed - indexed for MEDLINE]
17.

Clinical results using biochemotherapy as a standard of care in advanced melanoma.

Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ.

Melanoma Res. 2002 Aug;12(4):381-7.

PMID:
12170188
[PubMed - indexed for MEDLINE]
18.

Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.

Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, Boucher KM, Samlowski WE.

Cancer. 2007 Sep 15;110(6):1329-37.

PMID:
17623835
[PubMed - indexed for MEDLINE]
Free Article
19.

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS.

J Clin Oncol. 1998 Mar;16(3):1103-11.

PMID:
9508197
[PubMed - indexed for MEDLINE]
20.

Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.

Richtig E, Ludwig R, Kerl H, Smolle J.

Br J Dermatol. 2005 Nov;153(5):925-31.

PMID:
16225601
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk